

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
15 September 2005 (15.09.2005)

PCT

(10) International Publication Number  
**WO 2005/084635 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 9/00**
- (21) International Application Number: **PCT/GB2005/000806**
- (22) International Filing Date: **2 March 2005 (02.03.2005)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**0404693.4** **2 March 2004 (02.03.2004)** **GB**
- (71) Applicants (for all designated States except US): **INSTITUTE OF OPHTHALMOLOGY [GB/GB]; University of College London, 11-43 Bath Street, London EC1V 9EL (GB). MOORFIELDS EYE HOSPITAL NHS FOUNDATION TRUST [GB/GB]; 162 City Road, London EC1V 2PD (GB).**
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **DANIELS, Julie [GB/GB]; Division of Pathology, Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL (GB). WATSON, Stephanie [AU/AU]; 15 Somerset Avenue, North Turramurra, NSW 2074 (AU). GEERLING, Gerd [DE/DE]; Department of Ophthalmology, University of Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, D-23538 Luebeck (DE). DART, John [GB/GB]; Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London EC1V 2PD (GB).**
- (74) Agents: **SILVESTON, Judith et al.; Abel & Imray, 20 Red Lion Street, London WC1R 4PQ (GB).**
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.**
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): **ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**
- Declaration under Rule 4.17:**  
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **PHARMACEUTICAL PREPARATIONS FOR AND TREATMENT OF OCULAR SURFACE AND OTHER DISORDERS**

(57) Abstract: A pharmaceutical preparation suitable for use in the eye, which comprises: (i) a pharmaceutically acceptable carrier suitable for use in the eye; (ii) one or more ingredients selected from factors and agents that promote any one or more of survival, health, cell attachment and normal differentiation of ocular surface epithelial cells and optionally factors and agents to prevent squamous metaplasia; (iii) one or more agents capable of altering the fluid properties of a tear film including at least one agent capable of establishing and/or maintaining a stable tear film and optionally one or more agents selected from ophthalmological lubricating agents, viscosity enhancing agents and agents capable of reducing tear film evaporation; the factors and agents in component (ii) and (iii) being synthetic or recombinant or licensed for pharmaceutical use.

WO 2005/084635 A2